For the Inventor, By the Inventor

Enter assignee name

Kansas City, MO, United States of America

Biomed Valley Discoveries, Inc.

USPTO Granted Patents = 40

CIPO Patents = 2

EPO Patents = 15

Trademarks = 3

Forward Citations = 70

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Saurabh Saha (33 out of 37 patents)

Dean Welsch (20 out of 20 patents)

Gary DeCrescenzo (19 out of 19 patents)

4. Xiaoyan Michelle Zhang (16 out of 17 patents)

5. Zhongyu Zhu (15 out of 50 patents)

6. Dimiter Stanchev Dimitrov (15 out of 97 patents)

7. Brad St Croix (10 out of 17 patents)

8. Enrique Zudaire (10 out of 13 patents)

9. Jeffrey James Roix (10 out of 10 patents)

10. Rossitza Gueorguieva Alargova (5 out of 24 patents)

11. Irina Nikolaevna Kadiyala (5 out of 19 patents)

12. Petinka I Vlahova (5 out of 25 patents)

13. Stephan X M Boerrigter (5 out of 5 patents)

14. Alexander Aronov (5 out of 13 patents)

15. Ali Keshavarz-Shokri (5 out of 33 patents)

Core Competencies:

C. Novyi

Solid Tumors

Anti-CTLA-4 Antibodies

Anti-PD-1 Antibodies

CDK Inhibitors

ERK Inhibitors

Anti-CD276 Antibodies

Tumor-Associated Stroma

Immune Checkpoint Inhibitors

Chimeric Antigen Receptors

PI3K/Akt Pathway

Gliomas

40 patents: Sort by Forward Citations

1. 12433920 - C. novyi for the treatment of solid tumors in non-human animals (2025-10-07),

2. 12427173 - Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies (2025-09-30),

3. 12187698 - Crystalline forms of CHClNO (2025-01-07),

4. 12076324 - Cancer treatments using combinations of CDK and ERK inhibitors (2024-09-03),

5. 11851498 - Anti-CD276 antibodies (B7H3) (2023-12-26),

6. 11679112 - Cancer treatments using combinations of CDK and ERK inhibitors (2023-06-20),

7. 11512138 - Anti-CD276 polypeptides, proteins, and chimeric antigen receptors (2022-11-29),

8. 11439669 - C. novyi for the treatment of solid tumors in humans (2022-09-13),

9. 11390600 - Crystalline forms of CHClNO (2022-07-19),

10. 11246859 - Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers (2022-02-15),

11. 11135225 - Cancer treatments using combinations of CDK and ERK inhibitors (2021-10-05),

12. 11034757 - Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature (2021-06-15),

13. 11033621 - Combination therapies targeting tumor-associated stroma or tumor cells (2021-06-15),

14. 11033620 - Combination therapies targeting tumor-associated stroma or tumor cells and microtubules (2021-06-15),

15. 11033537 - LPT-723 and immune checkpoint inhibitor combinations and methods of treatment (2021-06-15),

Biomed Valley Discoveries, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative therapies for various diseases. We focus on translating scientific breakthroughs into transformative treatments that can improve patient outcomes. With a dedicated team of researchers and a collaborative approach, we aim to make a significant impact on the future of medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

40 Patents

#12 in Kansas City, MO

#104 in Missouri

#8,350 in US

#16,572 in the World

Kansas City, MO, United States of America

Biomed Valley Discoveries, Inc.

Forward Citations = 70

32 inventors:

Saurabh Saha (33 out of 37 patents)

Dean Welsch (20 out of 20 patents)

Gary DeCrescenzo (19 out of 19 patents)

4. Xiaoyan Michelle Zhang (16 out of 17 patents)

5. Zhongyu Zhu (15 out of 50 patents)

Please report any incorrect information to support@idiyas.com

Loading…